Novartis, a multinational pharmaceutical company, completed the acquisition of DTx Pharma, a privately held biotechnology company, for $1bn. Financial terms were not disclosed. “We look forward to continuing the development of DTx’s therapeutic programs and bringing new hope to patients with neuromuscular and other neurological disorders for which there have historically been few treatment options. We are also excited to bring DTx’s FALCON technology to Novartis and explore its potential to deliver drugs to extrahepatic tissues,” Fiona Marshall, Novartis Institutes for BioMedical Research President.